Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)

NCT03653832 PHASE3 COMPLETED

Many patients in intensive care (ICU) need help to breathe on a breathing machine and need pain killers and sedatives to keep them comfortable and pain free. However, keeping patients too deeply sedated can make their ICU stay longer, can cause ICU confusion (delirium) and afterwards may cause distressing memories. Ideally patients should be kept less sedated, but it is difficult to get the balance of sedation and comfort right. The investigators want to know whether starting an alpha2-agonist drug early in ICU can help keep patients more lightly sedated but still comfortable, and whether patients spend less time on the ventilator. The investigators also want to know how safe they are and if they can improve important outcomes during ICU stay and during recovery. The investigators also want to know if they are value for money.

Details

Lead sponsor	University of Edinburgh
Phase	PHASE3
Status	COMPLETED
Enrolment	1437
Start date	Mon Dec 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jul 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Critical Illness

Interventions

• Dexmedetomidine
• Clonidine
• Propofol

Countries

United Kingdom